VB-201: Phase II data

VBL discontinued development of VB-201 to treat psoriasis after top-line data from a double-blind, European Phase II trial in 194 patients

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE